KOL | Elijah B SaundersUniversity of Maryland School of Medicine, Baltimore, MD, USA | From the University of Washington, Seattle, Washington; Berry Consultants, Miami, Florida; University of ... |
KOL Resume for Elijah B Saunders
| Year | |
|---|---|
| 2017 | University of Maryland School of Medicine, Baltimore, MD, USA |
| 2016 | From the University of Washington, Seattle, Washington; Berry Consultants, Miami, Florida; University of Central Florida College of Medicine, Orlando, Florida; Berry Consultants, Austin, Texas; University of Maryland School of Pharmacy and School of Medicine, Baltimore, Maryland; Evidera, Montreal, Quebec, Canada, and Bethesda, Maryland; and University of Texas School of Public Health, Houston, Texas. |
| 2015 | University of Maryland Medical Center, Baltimore, MD Board of Trustees, International Society of Hypertension in Blacks (ISHIB), Arlington, VA |
| 2013 | Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA |
| 2012 | the Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD Division of Cardiology, Department of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA |
| 2011 | Section of Hypertension, University of Maryland School of Medicine, Baltimore, Maryland |
| 2010 | Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA |
| 2009 | From the Association of Black Cardiologists, Atlanta, GA ; 1Wayne State University, Detroit, MI ; 2University of Maryland, Baltimore, MD ; 3University of Texas Southwestern Medical Center, Dallas, TX ; 4UCLA Medical Center, Los Angeles, CA ; 5 and Pfizer Inc, New York, NY6 |
| 2008 | University of Maryland, Baltimore, New York, NY |
| 2007 | From the Section of Hypertension, University of Maryland School of Medicine, Baltimore, MD;1 New Orleans Center for Clinical Research, New Orleans, LA;2 Tulane University, New Orleans, LA;3 and Mylan Pharmaceuticals, Morgantown, WV4 Division of Hypertension, University of Maryland Medical System, Baltimore, MD, United States |
| 2006 | University of Maryland School of Medicine, Baltimore, MD 21201, USA. |
| 2005 | Section of Hypertension, University of Maryland School of Medicine, Baltimore (Dr Saunders). University of Maryland School of Medicine, Baltimore, MD; |
| 2004 | From the Department of Internal Medicine (E.M.), Department of Internal Medicine, Division of Endocrinology, Metabolism, and Hypertension (S.E.O., S.A.N., J.M.F.), Department of Internal Medicine, Academic Hospitalist Program (T.S.), Department of Internal Medicine, Division of Nephrology (E.C.), and Department of Internal Medicine, Cardiovascular Epidemiology and Clinical Applications (A.D.), Wayne State University, Detroit, Mich; Department of Medicine (E.S.), University of Maryland School of Medicine, Baltimore, Md. Division of Cardiology, University of Maryland School of Medicine, 419 West Redwood Street, Baltimore, MD 21201-1734, USA. |
| 2003 | Division of Cardiology, University of Maryland School of Medicine (ES), Baltimore, Maryland, USA |
| 2001 | From the *Division of Cardiovascular Medicine, State University of New York Health Science Center, Brooklyn, New York; †Xavier University, New Orleans, Louisiana; ‡School of Medicine, Wayne State University, Detroit, Michigan; §Howard Hughes Medical Institute, Chevy Chase, Maryland; ∥School of Medicine, Emory University, Atlanta, Georgia; ¶University of Pennsylvania, Philadelphia; **Morehouse School of Medicine, Atlanta, Georgia; ††School of Medicine, University of Maryland, Baltimore; ‡‡Stanford University Medical Center, California; §§University of California at Los Angeles; and ∥∥Case Western Reserve University, Cleveland, Ohio. Hypertension Division, University of Maryland Medical Center, Baltimore, Maryland U.S.A. |
| 2000 | Department of Hypertension, University of Maryland Medical Center, Baltimore 21201, USA. |
| 1998 | Clinical Research Unit and the Divisions of Nephrology and Hypertension, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA |
| 1996 | University of Maryland School of Medicine, Baltimore, MD. |
| 1995 | From the Clinical Research Unit and the Divisions of Nephrology and Hypertension, Department of Medicine, University of Maryland School of Medicine, Baltimore; James M. Gray and Associates, Houston, Tex; and Dean Medical Center, Oregon, Wis. A complete list of the participants in the Trandolapril Multicenter Study Group appears at the end of this article. Department of Medicine, Division of Hypertension, University of Maryland School of Medicine, Baltimore, Maryland, USA |
| 1991 | Department of Medicine, University of Maryland School of Medicine and Hospita, Baltimore, Md., USA Associate Professor of Medicine, Head, Division of Hypertension, University of Maryland Hospital and School of Medicine, Baltimore, Maryland |
| 1990 | Departments of Medicine, University of Maryland Hospital, Baltimore, Maryland |
| 1989 | From the University of Southern California, Los Angeles, California USA |
| 1988 | From the Divisions of Nephrology and Hypertension, Department of Internal Medicine, University of Maryland Hospital, Baltimore, Maryland, USA |
| 1987 | Associate Professor of Medicine and Head, Division of Hypertension, University of Maryland Hospital and School of Medicine, Baltimore, Maryland From the St. Paul-Ramsey Medical Center, St. Paul, Minnesota U.S.A. |
| 1986 | Division of Hypertension, University of Maryland Hospital and School of Medicine, Baltimore, Maryland, USA |
Elijah B Saunders: Influence Statistics
| Concept | World rank |
|---|---|
| black patient frequency | #1 |
| diuretic therapy agents | #1 |
| diuretics whites | #1 |
| diuretics antihypertensive therapy | #1 |
| united states responsiveness | #1 |
| african sidbp | #1 |
| african americans hctz | #1 |
| terazosin baseline | #1 |
| methyclothiazide 25 5 | #1 |
| inhibition black | #1 |
| terazosin series | #1 |
| patients proper combinations | #1 |
| trials blacks | #1 |
| baseline terazosin | #1 |
| methyclothiazide terazosin | #1 |
| terazosin methyclothiazide | #1 |
| special black patient | #1 |
| hypertension earlier onset | #1 |
| atenolol captopril | #1 |
| beta blockers classes | #1 |
| pooled sitting | #1 |
| sitting dbp trough | #1 |
| acute event goals | #1 |
| responsiveness black hypertensive | #1 |
| quinapril black | #1 |
| terazosin antihypertensive agents | #1 |
| squares sidbp | #1 |
| black hypertensives diuretics | #1 |
| 1 80 day | #1 |
| nebivolol 12 weeks | #1 |
| 1180 black patients | #1 |
| nebivolol stage | #1 |
| study african patients | #1 |
| hypertension multifaceted nature | #1 |
| low dose diuretics | #1 |
| placebo nebivolol monotherapy | #1 |
| black hypertensive complications | #1 |
| 300 african patients | #1 |
| diuretics blacks | #1 |
| 5 methyclothiazide | #1 |
| tolerability black patients | #1 |
| blacks diuretics | #1 |
Open the FULL List in Excel | |
Prominent publications by Elijah B Saunders
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
[ PUBLICATION ]
OBJECTIVES: The purpose of this study was to evaluate the efficacy and tolerability of monotherapy with the selective aldosterone blocker eplerenone in both black and white patients with hypertension.
BACKGROUND: Essential hypertension and cardiovascular-renal-target organ damage is more prevalent in black than white adults in the U.S.
METHODS: Black (n = 348) and white (n = 203) patients with mild-to-moderate hypertension were randomized to double-blind treatment with eplerenone 50 mg, ...
| Known for Eplerenone Placebo | White Patients | Losartan Dbp | Angiotensin Receptor | Efficacy Tolerability |
This multicenter, prospective, open-label, single-arm study determined the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients (n=1005), aged 18 years and older, with uncontrolled systolic blood pressure (SBP) of 140-159 mm Hg (130-159 mm Hg for type 2 diabetes mellitus) after at least 4 weeks of antihypertensive monotherapy. Treatment was sequential: placebo (4-5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 weeks), and ...
| Known for Systolic Blood | Inclusive Trial | Irbesartan Hctz | Mm Hg | Fixed Combinations |
Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes
[ PUBLICATION ]
This subgroup analysis of the Irbesartan/Hydrochlorothiazide (HCTZ) Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/HCTZ fixed combinations in adults with uncontrolled systolic blood pressure (SBP) (140-159 mm Hg; 130-159 mm Hg for type 2 diabetes mellitus [T2DM]) after >or=4 weeks of antihypertensive monotherapy. Treatment was sequential: placebo (4-5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 ...
| Known for Metabolic Syndrome | Type 2 | Antihypertensive Efficacy | Irbesartan Hctz | 8 Weeks |
BACKGROUND: African Americans with hypertension, particularly those with more severe blood pressure elevations, are generally less responsive to monotherapy from any antihypertensive class. These patients usually require treatment with drugs from > or = 2 antihypertensive classes to achieve adequate blood pressure control.
OBJECTIVE: The purpose of this study was to assess the antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide (HCTZ) in ...
| Known for African Americans | Antihypertensive Efficacy | Combination Hydrochlorothiazide | Mm Hg | Losartan Hctz |
Since the first International Society on Hypertension in Blacks consensus statement on the "Management of High Blood Pressure in African American" in 2003, data from additional clinical trials have become available. We reviewed hypertension and cardiovascular disease prevention and treatment guidelines, pharmacological hypertension clinical end point trials, and blood pressure-lowering trials in blacks. Selected trials without significant black representation were considered. In this ...
| Known for Blood Pressure | Hypertension Blacks | Cardiovascular Disease | Target Organ Damage | Mm Hg |
OBJECTIVE: To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans.
PATIENTS AND METHODS: Conducted between July 19, 2004, and August 9, 2005, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points trial was a 20-week, open-label, noncomparative, multicenter trial of the efficacy and safety of single-pill amlodipine/atorvastatin ...
| Known for African Americans | Blood Pressure | Drug Therapy | Amlodipine Atorvastatin | Efficacy Safety |
BACKGROUND: Nebivolol is a β(1)-selective β-blocker with NO-mediated vasodilatory properties, approved in the United States for the treatment of stage I-II hypertension.
OBJECTIVE: The purpose of this pooled analysis was to summarize efficacy and provide a brief overview of the tolerability associated with the use of nebivolol.
METHODS: PubMed was searched for randomized, double-blind, placebo-controlled, parallel-group trials of monotherapy with nebivolol for stage I-II hypertension of ...
| Known for Efficacy Tolerability | Mm Hg Dbp | Hypertension Nebivolol | Randomized Placebo | Blind Treatment |
African Americans have the highest overall mortality rate from coronary heart disease (CHD) of any ethnic group in the United States, particularly out-of-hospital deaths, and especially at younger ages. Although all of the reasons for the excess CHD mortality among African Americans have not been elucidated, it is clear that there is a high prevalence of certain coronary risk factors, delay in the recognition and treatment of high-risk individuals, and limited access to cardiovascular ...
| Known for African Americans | Coronary Heart Disease | United States Chd | Highrisk Individuals | Ethnic Differences |
BACKGROUND: Effectively reducing cardiovascular disease disparities requires identifying and reducing disparities in risk factors. Improved understanding of hypertension disparities is critical.
METHODS: Cross-sectional analysis of nationally representative samples of black and white adults 20 years and older who participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2002 (white, n = 4624; black, n = 1837) and NHANES III conducted in 1988-1994 (white, n = ...
| Known for Hypertension Prevalence | Racial Disparities | Awareness Treatment | Black White | Continental Ancestry |
BACKGROUND: There is limited information in the literature about reasons for discharges against medical advice (DAMA) as supplied by patients and providers. Information about the reasons for DAMA is necessary for identifying workable strategies to reduce the likelihood and health consequences of DAMA. The objective of this study is to identify the reasons for DAMA based on patient and multicategory provider focus-group interviews (FGIs).
METHODS: Patients who discharged against medical ...
| Known for Medical Advice | Reasons Dama | Qualitative Study | Patients Providers | Health Patient |
The antihypertensive effect of the angiotensin-converting enzyme inhibitor trandolapril administered in doses of 1, 2, and 4 mg/d was compared in 207 white patients and 91 black patients with mild to moderate hypertension following a double-blind, randomized, placebo-controlled, parallel study design. Trandolapril is a prodrug that is rapidly hydrolyzed to its active diacid metabolite, trandolaprilat. After 6 weeks of double-blind treatment, trandolapril lowered baseline sitting ...
| Known for Converting Enzyme | Black Patients | Antihypertensive Response | Dose Trandolapril | Blood Pressure |
Advances in heart failure treatment have not necessarily translated into equity in improved outcomes for African Americans. Heart failure in African Americans is characterized by a higher prevalence, especially at younger ages; more-adverse course with more frequent hospitalizations; and higher mortality rates compared to the general population. Despite this distinct disease profile, African Americans are remarkably underrepresented in large heart failure trials. This paper reviews the ...
| Known for African Americans | Heart Failure | Large Clinical Trials | Humans Risk | Higher Mortality |
The IrbesartaN/hydroChlorothiazide (HCTZ) bLood pressUre reductionS In diVErse patient populations (INCLUSIVE) trial was a multicenter, prospective, open-label, single-arm study evaluating the efficacy and safety of irbesartan/HCTZ fixed combinations in patients > or = 18 years old with uncontrolled systolic blood pressure (SBP, 140-159 mmHg; 130-159 mmHg for type-2 diabetes mellitus patients) after > or = 4 weeks of antihypertensive monotherapy. This analysis focused on different ...
| Known for Blood Pressure | Fixed Combinations | Irbesartan Hctz | Antihypertensive Monotherapy | 4 Weeks |
Key People For African Americans
Elijah B Saunders:Expert Impact
Concepts for whichElijah B Saundershas direct influence:African americans, Metabolic syndrome, Blood pressure, Blood pressure response, Cardiovascular disease, Black patients, Medical advice, Qualitative study.
Elijah B Saunders:KOL impact
Concepts related to the work of other authors for whichfor which Elijah B Saunders has influence:Blood pressure, African americans, Metabolic syndrome, Heart failure, Cardiovascular disease, Combination therapy, United states.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |